[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339386-105":59,"doc-detail-339386-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunologic-tumor-microenvironment-modulators-for-turning-cold-tumors-hot","Immunologic tumor microenvironment modulators for turning cold tumors hot","","Tumors can be classified by cytotoxic immune-cell presence and spatial organization within the tumor microenvironment (TME). Hot tumors show heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), unlike cold tumors with poor immune infiltration and therapy resistance. Immunologic modulators, especially CTLA-4 and PD-1/PD-L1 targeting agents, disrupt inhibitory signals and reactivate antitumor immunity, converting cold to hot phenotypes. Persistent issues include primary resistance, immune-related adverse events, and heterogeneous tumor responses, requiring deeper mechanistic strategies and combination immune approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunologic-tumor-microenvironment-modulators-for-turning-cold-tumors-hot/339386/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunologic-tumor-microenvironment-modulators-for-turning-cold-tumors-hot/339386.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How are hot and cold tumors distinguished in immunotherapy contexts?","Question",{"text":112,"@type":113},"Hot tumors have heightened immune activity and respond to immune checkpoint inhibitors, while cold tumors lack immune infiltration and remain resistant to therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which immune checkpoint targets are emphasized for converting cold tumors to hot ones?",{"text":117,"@type":113},"The review highlights CTLA-4 and the PD-1/PD-L1 axis as key targets for disrupting inhibitory signals and reactivating immune responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What major challenges limit immunotherapy effectiveness?",{"text":121,"@type":113},"Primary resistance, autoimmune side effects, and tumor response heterogeneity are described as persistent challenges requiring improved strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339386,1790212027,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","DOI: 10.1002/cac2.12539  \nREVIEW  \nImmunologic tumor microenvironment modulators for turning cold tumors hot  \nGholam-Reza Khosravi1  Samaneh Mostafavi2 Narges Ebrahimi1  Roya Safari Gharibvand3  \nSanaz Bastan1  Nahid Eskandari1   \n1 Department of Medical Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran  \n2 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran  \n3 Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran  \nCorrespondence  \nNahid Eskandari; Department of Immunology, Isfahan University of Medical Sciences, Isfahan. [Email:](Email: neskandari@med.mui.ac.ir)[ neskandari@med.mui.ac.ir](Email: neskandari@med.mui.ac.ir)  \nAbstract  \nTumors can be classified into distinct immunophenotypes based on the presence and arrangement of cytotoxic immune cells within the tumor microenvironment (TME) . Hot tumors, characterized by heightened immune activity and responsiveness to immune checkpoint inhibitors (ICIs), stand in stark contrast  \nList of abbreviations: ACAT, acetyl-coA acetyltransferase; ACT, adoptive cell therapy; ADT, androgen deprivation therapy; AP2, adipocyte protein 2; APC, antigen-presenting cell; APM, antigen processing machinery; AT, adipose tissues; ATP, adenosine triphosphate; B2M, beta-2-microglobulin; BATF, basic leucine zipper transcriptional factor ATF-like; CAA, cancer-associated adipocyte; CAF, cancer-associated fibroblast; CAR, chimeric antigen receptor; cDC, conventional DC; COAD, colon adenocarcinoma; COX, cyclooxygenase; CRS, cytokine release syndrome; CRT, calreticulin; CSF, colony-stimulating factor; CTA, cancer/testis antigen; CTL, cytotoxic T lymphocyte; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCL, C-X-C motif chemokine ligand; CXCR, C-X-C chemokine receptor; DAMP, danger associated molecular pattern; DC, dendritic cell; DLN, draining lymph node; ECM, extracellular matrix; FABP4, fatty acid-binding protein 4; FAP, fibroblast activation protein; FDA, food and drug administration; FGF2, fibroblast growth factor 2; FLT3L, Fms-like tyrosine kinase 3 ligand; FRβ, folate receptor beta; G-CSf, granulocyte-colony stimulating factor; GLUT, glucose-transporter; GM-CSF, granulocyte-macrophage-colony stimulating factor; HCC, hepatocellular carcinoma; HIF, hypoxia-inducible factor; HMGB, high mobility group box; HPV, human papillomavirus; HSC, hematopoietic stem cell; HSP, heat shock protein; ICB, immune checkpoint blockade; ICD, immunogenic cell death; ICI, immune checkpoint inhibitor; IDO, indoleamine 2, 3-dioxygenase; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; irAE, immune-related adverse event; IRF, interferon regulatory factor; ITH, intratumoral heterogeneity; JAK, Janus Kinase; LAT, L-type amino acid transporter; LDH, lactate dehydrogenase; LNP, lipid nanoparticle; LT, lymphotoxin; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; MDSC, myeloid-derived suppressor cell; MerTK, Mer receptor tyrosine kinase; MHC, major histocompatibility complex; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; MMR, mismatch repair; MSC, mesenchymal stem cell; mTOR, mammalian target of rapamycin; NAD+ , nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NBR1, neighbor of BRCA1 gene 1; NF-κB, nuclear factor-kappa B; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; OXPHOS, oxidation phosphorylation; PAMP, pathogen-associated molecular pattern; PBMC, peripheral blood mononuclear cell; PD-1, programmed cell death protein 1; PDAC, pancreatic ductal adenocarcinoma; pDC, plasmacytoid DC; PDGF, platelet-derived growth factor; PD-L1, programmed death-ligand 1; PET, positron emission tomography; PRR, pattern recognition receptor; PRS, polygenic risk score; ROS, reactive oxygen species; SIRP, signal-regulatory protein; STAT, signal transducer and activator of transcription; S","cbCait3vLEhh97AH","https://ap.wps.com/l/cbCait3vLEhh97AH","pdf",2129119,33,"English","## Immunophenotypes in the tumor microenvironment\n## Cold versus hot tumors and immunotherapy responsiveness\n## Immunologic modulators and checkpoint targeting\n## Challenges and combination strategies","[{\"question\":\"How are hot and cold tumors distinguished in immunotherapy contexts?\",\"answer\":\"Hot tumors have heightened immune activity and respond to immune checkpoint inhibitors, while cold tumors lack immune infiltration and remain resistant to therapy.\"},{\"question\":\"Which immune checkpoint targets are emphasized for converting cold tumors to hot ones?\",\"answer\":\"The review highlights CTLA-4 and the PD-1/PD-L1 axis as key targets for disrupting inhibitory signals and reactivating immune responses.\"},{\"question\":\"What major challenges limit immunotherapy effectiveness?\",\"answer\":\"Primary resistance, autoimmune side effects, and tumor response heterogeneity are described as persistent challenges requiring improved strategies.\"}]","Immunologic tumor microenvironment modulators for turning cold tumors hot | PDF",1790029947,83,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5bac8a4f16ec845b712e5b0e93fcbf7.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/193d723d221f4a59894631bf787268f9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eab52c87e9c87a31ab39e03534c4d45e.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f35af5af95d8876542ed485070f7c0b1.webp",980,1287]